Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by J. Schulze zur Wiesch
High Efficacy of Sofosbuvir/Velpatasvir and Impact of Baseline Resistance-Associated Substitutions in Hepatitis C Genotype 3 Infection
Alimentary Pharmacology and Therapeutics
Hepatology
Pharmacology
Gastroenterology
Editorial: Genotype 3 HCV-who Still Needs Ribavirin in a Pan-Genotypic Era? Authors’ Reply
Alimentary Pharmacology and Therapeutics
Hepatology
Pharmacology
Gastroenterology
Related publications
Efficacy of Sofosbuvir, Velpatasvir, and GS-9857 in Patients With Genotype 1 Hepatitis C Virus Infection in an Open-Label, Phase 2 Trial
Gastroenterology
Hepatology
Gastroenterology
Sofosbuvir/Velpatasvir for Chronic Hepatitis C Infection in Patients With Transfusion-Dependent Thalassemia
American Journal of Hematology
Hematology
Prevalence of Resistance Associated Substitutions and Efficacy of Baseline Resistance-Guided Chronic Hepatitis C Treatment in Spain From the GEHEP-004 Cohort
PLoS ONE
Multidisciplinary
NS5A-P32 Deletion After Failure of Ledipasvir/Sofosbuvir in Hepatitis C Virus Genotype 1b Infection
Hepatology
Medicine
Hepatology
Efficacy of the Combination of Sofosbuvir, Velpatasvir, and the NS3/4A Protease Inhibitor GS-9857 in Treatment-Naïve or Previously Treated Patients With Hepatitis C Virus Genotype 1 or 3 Infections
Gastroenterology
Hepatology
Gastroenterology
Sofosbuvir-Velpatasvir-Voxilaprevir With or Without Ribavirin in Direct-Acting Antiviral-Experienced Patients With Genotype 1 Hepatitis C Virus
Hepatology
Medicine
Hepatology
Baseline Hepatitis C Virus Resistance-Associated Substitutions Present at Frequencies Lower Than 15% May Be Clinically Significant
Infection and Drug Resistance
Infectious Diseases
Pharmacology
Efficacy of Glecaprevir and Pibrentasvir in Patients With Genotype 1 Hepatitis C Virus Infection With Treatment Failure After NS5A Inhibitor Plus Sofosbuvir Therapy
Gastroenterology
Hepatology
Gastroenterology
Efficacy and Safety of Generic Daclatasvir + Sofosbuvir ± Ribavirin in Treatment of Genotype 3 Infected Hepatitis C Patients - A Real Life Experience From Pakistan
Hepatoma Research
